Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine

被引:45
作者
Zhu, Min [1 ]
Kaul, Sanjeev [1 ]
Nandy, Partha [1 ]
Grasela, Dennis M. [1 ]
Pfister, Marc [1 ]
机构
[1] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ 08543 USA
关键词
PRIMARY HUMAN HEPATOCYTES; POPULATION PHARMACOKINETICS; CYP2B6; CYP3A4; METABOLISM; EXPRESSION; NELFINAVIR; INDINAVIR; RECEPTOR; THERAPY;
D O I
10.1128/AAC.01120-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Characterization of the time course and magnitude of enzyme induction due to multiple inducers is important for interpretation of clinical data from drug-drug interaction studies. A population interaction model was developed to quantify efavirenz autoinduction and further induction with concurrent carbamazepine coadministration. Efavirenz concentration data in the absence and presence of carbamazepine following single- and multiple-dose oral administrations in healthy subjects were used for model development. The proposed model was able to describe the time-dependent efavirenz autoinduction and the further induction with carbamazepine when the agents were combined. The estimated population averages of efavirenz oral clearance were 5.5, 9.4, 14.4, and 16.7 liters/h on days 1, 14, and 35 and at steady state for the interaction, respectively, for efavirenz monotherapy for 2 weeks followed by the coadministration of carbamazepine for 3 weeks. The estimated times to 50% of the steady state for efavirenz autoinduction and for the induction resulting from the concurrent administration of efavirenz and carbamazepine were similar (around 10 to 12 days). With this model-based analysis, efavirenz exposures can be projected prior to and at the steady state of induction, allowing a better understanding of the time course and magnitude of enzyme induction.
引用
收藏
页码:2346 / 2353
页数:8
相关论文
共 33 条
[1]   Efavirenz [J].
Adkins, JC ;
Noble, S .
DRUGS, 1998, 56 (06) :1055-1064
[2]   Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy [J].
Barrett, JS ;
Labbé, L ;
Pfister, M .
CLINICAL PHARMACOKINETICS, 2005, 44 (06) :591-625
[3]  
Barrett JS, 2002, INT J CLIN PHARM TH, V40, P507
[4]  
Beal SS, 1989, NONMEM User's Guides
[5]   Dose-dependent metabolism of carbamazepine in humans [J].
Bernus, I ;
Dickinson, RG ;
Hooper, WD ;
Eadie, MJ .
EPILEPSY RESEARCH, 1996, 24 (03) :163-172
[6]   Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage [J].
Bondareva, I. B. ;
Jelliffe, R. W. ;
Gusev, E. I. ;
Guekht, A. B. ;
Melikyan, E. G. ;
Belousov, Y. B. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (03) :211-221
[7]   Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism [J].
Burger, D ;
van der Heiden, I ;
la Porte, C ;
van der Ende, M ;
Groeneveld, P ;
Richter, C ;
Koopmans, P ;
Kroon, F ;
Sprenger, H ;
Lindemans, J ;
Schenk, P ;
van Schaik, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (02) :148-154
[8]   Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection [J].
Csajka, C ;
Marzolini, C ;
Fattinger, K ;
Décosterd, LA ;
Fellay, J ;
Telenti, A ;
Biollaz, J ;
Buclin, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :20-30
[9]  
Desta Z, 2007, CLIN PHARMACOL THER, V81, pS99
[10]  
DESTA Z, 2003, CYP2B6 DRUG INTERACT